Loss of frataxin activates the iron/sphingolipid/PDK1/Mef2 pathway in mammals

eLife

Volumn 5, Issue NOVEMBER2016, 2016, Pages

  Chen, Kuchuan ^a   Ho, Tammy Szu Yu ^a   Lin, Guang ^a   Tan, Kai Li ^a   Rasband, Matthew N ^a   Bellen, Hugo J ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Jan and Dan Duncan Neurological Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRATAXIN; IRON; MYOCYTE ENHANCER FACTOR 2; PARVOVIRUS VECTOR; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; SPHINGOLIPID; IRON BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CHILD; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; FRIEDREICH ATAXIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; MALE; MASS SPECTROMETRY; MOUSE; NEWBORN; NONHUMAN; PRESCHOOL CHILD; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROTAROD TEST; SCHOOL CHILD; UPREGULATION; WIRE HANG TEST; YOUNG ADULT; ANIMAL; GENE INACTIVATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; FRIEDREICH ATAXIA; GENE KNOCKOUT TECHNIQUES; HUMANS; IRON; IRON-BINDING PROTEINS; MEF2 TRANSCRIPTION FACTORS; MICE; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 85001075479     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.20732     Document Type: Article

References (42)

1. Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP. 2012. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19 (Suppl 1):43–44. doi: 10.3109/13506129.2012.673140, PMID: 22494066
2. Alonso-Montes C, Naves-Diaz M, Fernandez-Martin JL, Rodriguez-Reguero J, Moris C, Coto E, Cannata-Andia JB, Rodriguez I. 2012. New polymorphisms in human MEF2C gene as potential modifier of hypertrophic cardiomyopathy. Molecular Biology Reports 39:8777–8785. doi: 10.1007/s11033-012-1740-7, PMID: 22718505
3. Anderson JP, Dodou E, Heidt AB, De Val SJ, Jaehnig EJ, Greene SB, Olson EN, Black BL. 2004. HRC is a direct transcriptional target of MEF2 during cardiac, skeletal, and arterial smooth muscle development in vivo. Molecular and Cellular Biology 24:3757–3768. doi: 10.1128/MCB.24.9.3757-3768.2004, PMID: 15082771
4. Anderson PR, Kirby K, Hilliker AJ, Phillips JP. 2005. RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Human Molecular Genetics 14:3397–3405. doi: 10.1093/hmg/ddi367, PMID: 16203742
5. Ayala A, Muñoz MF, Argüelles S. 2014. Lipid peroxidation: production, metabolism, and signaling mechanisms of Malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Medicine and Cellular Longevity 2014:1–31. doi: 10.1155/2014/360438
6. Ayuso E, Mingozzi F, Montane J, Leon X, Anguela XM, Haurigot V, Edmonson SA, Africa L, Zhou S, High KA, Bosch F, Wright JF. 2010. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Therapy 17:503–510. doi: 10.1038/gt.2009.157, PMID: 19956269
7. Babcock M, de Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, Montermini L, Pandolfo M, Kaplan J. 1997. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276:1709–1712. doi: 10.1126/science.276.5319.1709, PMID: 9180083
8. Bayot A, Santos R, Camadro JM, Rustin P. 2011. Friedreich’s ataxia: the vicious circle hypothesis revisited. BMC Medicine 9:112. doi: 10.1186/1741-7015-9-112, PMID: 21985033
9. Boddaert N, Le Quan Sang KH, Rötig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI. 2007. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110: 401–408. doi: 10.1182/blood-2006-12-065433, PMID: 17379741
10. Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, Schapira AH. 2000. Clinical, biochemical and molecular genetic correlations in Friedreich’s ataxia. Human Molecular Genetics 9:275–282. doi: 10.1093/hmg/9.2.275, PMID: 10607838
11. Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Cañizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, et al. 1996. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271:1423–1427. doi: 10.1126/science.271.5254.1423, PMID: 8596916
12. Casamayor A, Morrice NA, Alessi DR. 1999. Phosphorylation of Ser-241 is essential for the activity of 3- phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochemical Journal 342:287–292. doi: 10.1042/bj3420287, PMID: 10455013
13. Chen K, Lin G, Haelterman NA, Ho TS, Li T, Li Z, Duraine L, Graham BH, Jaiswal M, Yamamoto S, Rasband MN, Bellen HJ. 2016. Loss of Frataxin induces iron toxicity, sphingolipid synthesis, and Pdk1/Mef2 activation, leading to neurodegeneration. eLife 5:e16043. doi: 10.7554/eLife.16043, PMID: 27343351
14. Ewen EP, Snyder CM, Wilson M, Desjardins D, Naya FJ. 2011. The Mef2A transcription factor coordinately regulates a costamere gene program in cardiac muscle. Journal of Biological Chemistry 286:29644–29653. doi: 10.1074/jbc.M111.268094, PMID: 21724844
15. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, Kay MA. 2008. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. Journal of Virology 82: 5887–5911. doi: 10.1128/JVI.00254-08, PMID: 18400866
16. Ho TS, Zollinger DR, Chang KJ, Xu M, Cooper EC, Stankewich MC, Bennett V, Rasband MN. 2014. A hierarchy of ankyrin-spectrin complexes clusters sodium channels at nodes of Ranvier. Nature Neuroscience 17:1664–1672. doi: 10.1038/nn.3859, PMID: 25362473
17. Koeppen AH, Morral JA, Davis AN, Qian J, Petrocine SV, Knutson MD, Gibson WM, Cusack MJ, Li D. 2009. The dorsal root ganglion in Friedreich’s ataxia. Acta Neuropathologica 118:763–776. doi: 10.1007/s00401-009-0589-x, PMID: 19727777
18. Koeppen AH. 2011. Friedreich’s ataxia: pathology, pathogenesis, and molecular genetics. Journal of the Neurological Sciences 303:1–12. doi: 10.1016/j.jns.2011.01.010, PMID: 21315377
19. Lee YJ, Huang X, Kropat J, Henras A, Merchant SS, Dickson RC, Chanfreau GF. 2012. Sphingolipid signaling mediates iron toxicity. Cell Metabolism 16:90–96. doi: 10.1016/j.cmet.2012.06.004, PMID: 22768841
20. Ljungberg MC, Ali YO, Zhu J, Wu CS, Oka K, Zhai RG, Lu HC. 2012. CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. Human Molecular Genetics 21:251–267. doi: 10.1093/hmg/ddr492, PMID: 22027 994
21. Llorens JV, Navarro JA, Martínez-Sebastián MJ, Baylies MK, Schneuwly S, Botella JA, Moltó MD. 2007. Causative role of oxidative stress in a Drosophila model of Friedreich ataxia. The FASEB Journal 21:333–344. doi: 10.1096/fj.05-5709com, PMID: 17167074
22. Macevilly CJ, Muller DP. 1997. Oxidative stress does not appear to be involved in the aetiology of Friedreich’s ataxia. Restorative Neurology and Neuroscience 11:131–137. doi: 10.3233/RNN-1997-11303, PMID: 21551537
23. Martelli A, Puccio H. 2014. Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation. Frontiers in Pharmacology 5:130. doi: 10.3389/fphar.2014.00130, PMID: 24917819
24. Mühlenhoff U, Richhardt N, Ristow M, Kispal G, Lill R. 2002. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Human Molecular Genetics 11:2025–2036. doi: 10.1093/hmg/11.17.2025, PMID: 12165564
25. Petrat F, Weisheit D, Lensen M, de Groot H, Sustmann R, Rauen U. 2002. Selective determination of mitochondrial chelatable iron in viable cells with a new fluorescent sensor. Biochemical Journal 362:137–147. doi: 10.1042/bj3620137, PMID: 11829750
26. Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng G, Sharp PA, et al. 2014. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159:440–455. doi: 10.1016/j.cell.2014.09.014, PMID: 25263330
27. Potthoff MJ, Arnold MA, McAnally J, Richardson JA, Bassel-Duby R, Olson EN. 2007. Regulation of skeletal muscle sarcomere integrity and postnatal muscle function by Mef2c. Molecular and Cellular Biology 27:8143–8151. doi: 10.1128/MCB.01187-07, PMID: 17875930
28. Puccio H, Simon D, Cossée M, Criqui-Filipe P, Tiziano F, Melki J, Hindelang C, Matyas R, Rustin P, Koenig M. 2001. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nature Genetics 27:181–186. doi: 10.1038/84818, PMID: 11175786
29. Rötig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, Munnich A, Rustin P. 1997. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nature Genetics 17:215–217. doi: 10.1038/ng1097-215, PMID: 9326946
30. Santhera Pharmaceuticals. 2010. A Phase III double-blind, randomised, Placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of friedreich’s ataxia patients. NCT00905268
31. Santos R, Lefevre S, Sliwa D, Seguin A, Camadro JM, Lesuisse E. 2010. Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxidants & Redox Signaling 13:651–690. doi: 10.1089/ars.2009.3015, PMID: 20156111
32. Seznec H, Simon D, Bouton C, Reutenauer L, Hertzog A, Golik P, Procaccio V, Patel M, Drapier JC, Koenig M, Puccio H. 2005. Friedreich ataxia: the oxidative stress paradox. Human Molecular Genetics 14:463–474. doi: 10.1093/hmg/ddi042, PMID: 15615771
33. Shidara Y, Hollenbeck PJ. 2010. Defects in mitochondrial axonal transport and membrane potential without increased reactive oxygen species production in a Drosophila model of Friedreich ataxia. Journal of Neuroscience 30:11369–11378. doi: 10.1523/JNEUROSCI.0529-10.2010, PMID: 20739558
34. Simon D, Seznec H, Gansmuller A, Carelle N, Weber P, Metzger D, Rustin P, Koenig M, Puccio H. 2004. Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. Journal of Neuroscience 24:1987–1995. doi: 10.1523/JNEUROSCI.4549-03.2004, PMID: 14985441
35. Solbach K, Kraff O, Minnerop M, Beck A, Schöls L, Gizewski ER, Ladd ME, Timmann D. 2014. Cerebellar pathology in Friedreich’s ataxia: atrophied dentate nuclei with normal iron content. NeuroImage: Clinical 6:93–99. doi: 10.1016/j.nicl.2014.08.018, PMID: 25379420
36. Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F. 2015. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nature Biotechnology 33:102–106. doi: 10.1038/nbt.3055, PMID: 25326897
37. Szu-Yu Ho T, Rasband MN. 2011. Maintenance of neuronal polarity. Developmental Neurobiology 71:474–482. doi: 10.1002/dneu.20843, PMID: 21557501
38. Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, Miki K, Yonenobu K, Ochi T, Noguchi K. 2000. Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: A novel neuronal marker of nerve injury. Molecular and Cellular Neuroscience 15:170–182. doi: 10.1006/mcne.1999.0814, PMID: 10673325
39. Woronicz JD, Lina A, Calnan BJ, Szychowski S, Cheng L, Winoto A. 1995. Regulation of the Nur77 orphan steroid receptor in activation-induced apoptosis. Molecular and Cellular Biology 15:6364–6376. doi: 10.1128/MCB.15.11.6364, PMID: 7565789
40. Xu J, Gong NL, Bodi I, Aronow BJ, Backx PH, Molkentin JD. 2006. Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. Journal of Biological Chemistry 281:9152–9162. doi: 10.1074/jbc.M510217200, PMID: 16469744
41. Zhang C, Susuki K, Zollinger DR, Dupree JL, Rasband MN. 2013. Membrane domain organization of myelinated axons requires bII spectrin. Journal of Cell Biology 203:437–443. doi: 10.1083/jcb.201308116, PMID: 24217619
42. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N. 1999. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 6:973–985. doi: 10.1038/sj.gt.3300938, PMID: 10455399